Loading clinical trials...
Loading clinical trials...
A Randomized, Multi-center, Double-blind, Cross-over Study Comparing the Efficacy and Safety of Focalin® XR 20 mg Versus Placebo at the 0.5 Hour Timepoint (Post-dose) in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting
Conditions
Interventions
Dex-methylphenidate hydrochloride extended-release (Focalin XR)
Placebo
Locations
5
United States
Novartis Investigative Site
Little Rock, Arkansas, United States
Novartis Investigative Site
Winter Park, Florida, United States
Novartis Investigative Site
Las Vegas, Nevada, United States
Novartis Investigative Site
Houston, Texas, United States
Novartis Investigative Site
Lubbock, Texas, United States
Start Date
October 1, 2007
Primary Completion Date
November 1, 2007
Completion Date
November 1, 2007
Last Updated
April 27, 2012
NCT07189442
NCT06123741
NCT06847165
NCT04175041
NCT07459699
NCT07439276
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions